SAS Output

10-APR-2021 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 1 Y 1 Ramucirumab + Carbo/Paclitaxel 66 6 3 0 0 0 0 03/20/2019 109 41
        2 Carboplatin + Paclitaxel   5 3 2 0 0 0      
            11 6 2 0 0 0      
 
  S1827-SCLC, MRI Surveillance +/- PCI 1 Y 1 PCI + MRI brain surveillance 668 16 16 10 5 1 1 05/04/2020 250 107
        2 MRI brain surveillance   17 17 9 5 1 1      
            33 33 19 10 2 2      
 
  S1900B-RET Fusion: Selpercatinib (LOXO-292) 1 Y 1 Selpercatinib (LOXO-292) 124 6 5 3 1 1 0 04/08/2020 257 122
            6 5 3 1 1 0      
 
  S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo 1 Y 1 Atezolizumab and SBRT 480 9 9 8 5 2 0 08/13/2020 236 89
        2 SBRT   10 10 9 6 3 1      
            19 19 17 11 5 1      
 
  S1929-ESCLC, SLFN11+, Atezolizumab Talazoparib 1 Y 0 Screening 94 73 73 53 28 5 1 07/20/2020 160 74
            73 73 53 28 5 1      
 
    2 Y 1 Atezolizumab 94 10 10 7 4 1 0 07/20/2020    
        2 Atezolizumab + Talazoparib   10 10 8 5 1 0      
            20 20 15 9 2 0      
 
  S1933-NSCLC, Stg II-III, RT + Atezo 1 Y 1 Hypofractionated Radiotherapy 47 2 2 2 2 0 0 01/13/2021 97 47
            2 2 2 2 0 0      
 
  LUNGMAP-NSCLC, Adv, Master 1 Y 1 Tissue Submission   1925 778 276 122 38 8 02/06/2019 356 182
            1925 778 276 122 38 8      
 
Yes A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO 1 E Total Registrations   9 9 9 5 2 1 10/20/2020 334 169
            9 9 9 5 2 1      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   853 47 28 11 5 2 12/16/2014 391 241
            853 47 28 11 5 2      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   16 2 1 0 0 0 02/29/2016 378 214
            16 2 1 0 0 0      
 
  EA5163-NSCLC, Immunotherapy +/- 2nd line therapy 1 E Total Registrations   34 17 11 4 3 1 05/30/2019 302 131
            34 17 11 4 3 1      
 
  EA5181-NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 1 E Total Registrations   13 13 10 5 3 2 08/03/2020 232 91
            13 13 10 5 3 2      
 
    2 E Total Registrations   7 7 7 3 1 1 08/03/2020    
            7 7 7 3 1 1      
 
  EA5191-NSCLC, Cabozantinib +/- Nivolumab vs Chemo 0 E Total Registrations   1 1 1 0 0 0 11/02/2020 162 64
            1 1 1 0 0 0      
 
    1 E Total Registrations   1 1 1 0 0 0 11/02/2020    
            1 1 1 0 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   4 0 0 0 0 0 10/20/2016 214 118
            4 0 0 0 0 0      
 
    2 E Total Registrations   4 0 0 0 0 0 10/20/2016    
            4 0 0 0 0 0      
 
  NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST 1 E Total Registrations   2 1 1 1 0 0 11/06/2019 261 126
            2 1 1 1 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   865 47 28 11 4 2 12/16/2014 391 241
            865 47 28 11 4 2      
 
  NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo 1 E Total Registrations   1 0 0 0 0 0 08/16/2019 338 147
            1 0 0 0 0 0      
 

10-APR-2021 6:10

LUNG Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S1900E KRAS G12C: AMG 510 1 Registration 02-Apr-21 59 27
S1933 NSCLC, Stg II-III, RT + Atezo 2 Consolidation 15-Jun-20 97 47